VRCA - NASDAQ
Verrica Pharmaceuticals Inc.
$6.15
+7.5%Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
At a Glance
Live SnapshotVerrica Pharmaceuticals Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Verrica Pharmaceuticals Inc. Income Statement
VRCA • NASDAQ
| Verrica Pharmaceuticals Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
35.6M | 7.6M | 5.1M | 9M | 12M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||
(3.4M) | (2.7M) | (746K) | (725K) | (472K) | (229K) | (257.2K) | (20.3K) | (0.0) | (0.0) | |
32.1M | 4.8M | 4.4M | 8.3M | 11.5M | -229K | -257.2K | -20.3K | 0.0 | 0.0 | |
OPERATING INCOME | ||||||||||
(44.1M) | (70.7M) | (70.1M) | (29.6M) | (42.4M) | (40M) | (29.8M) | (21.9M) | (4.5M) | (1.9M) | |
(35.2M) | (58.8M) | (47.3M) | (17.4M) | (27M) | (24.5M) | (14.4M) | (9.1M) | (727K) | (204K) | |
(8.9M) | (11.8M) | (20.3M) | (12.2M) | (15.9M) | (15.7M) | (15.4M) | (12.8M) | (3.7M) | (1.7M) | |
-11.9M | -65.9M | -65.8M | -21.3M | -30.9M | -40.2M | -30.1M | -21.9M | -4.5M | -1.9M | |
PRE-TAX INCOME | ||||||||||
(7.7M) | (9.4M) | (4M) | (2.2M) | (4.3M) | (3M) | (0.0) | (0.0) | (2K) | (0.0) | |
-6.8M | -8M | -1.2M | -1.7M | -4.2M | -2.5M | 1.9M | 0.0 | 0.0 | 0.0 | |
(0.0) | (83K) | (2.5M) | (0.0) | -472K | -229K | (0.0) | -1K | (0.0) | (0.0) | |
-5.9M | -10.7M | -1.2M | -3.2M | -4.2M | -2.5M | 1.9M | 1.2M | -2K | 0.0 | |
-17.9M | -76.6M | -67M | -24.5M | -35.1M | -42.7M | -28.2M | -20.6M | -4.5M | -1.9M | |
NET INCOME | ||||||||||
-17.9M | -76.6M | -67M | -24.5M | -35.1M | -45.5M | -28.2M | -20.6M | -4.5M | -1.9M |
SEC Filings
VRCA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 20, 2026 | June 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 11, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 30, 2025 | December 23, 2025 | 2025 | |
S-3 S-3 N/A | December 15, 2025 | December 15, 2025 | ||
8-K 8-K 2025 N/A | November 24, 2025 | November 23, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 14, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your VRCA research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.